Cosmetic Ingredient Review Report Status
This article was originally published in The Rose Sheet
Executive Summary
Chart: Data compiled by the Rose Sheet from information in CIR reports and the panel’s Dec. 5-6 meeting.
You may also be interested in...
CIR Panel Looks To Establish Guidelines For Read-Across Use
At its December meeting in Washington, the Cosmetic Ingredient Review Expert Panel finalized safety assessments for eight ingredients and advanced three other reports. In its reviews, the group made selective use of read-across data while agreeing to discuss protocol for employing the predictive approach in future reviews.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.